Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity

Hepatology

Volumn 44, Issue 1, 2006, Pages 53-61

  Lisman, Ton ^a,b   Bongers, Tamara N ^c   Adelmeijer, Jelle ^a   Janssen, Harry L A ^c   De Maat, Moniek P M ^c   De Groot, Philip G ^a,b   Leebeek, Frank W G ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GLYCOPROTEIN IB; RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE SEVERITY; FUNCTIONAL STATUS; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; THROMBOCYTE ADHESION;

BIOLOGICAL MARKERS; BIOPSY; ELECTROPHORESIS, AGAR GEL; HEMOSTASIS; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; PLATELET ADHESIVENESS; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 33745875950     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21231     Document Type: Article

References (30)

1. Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002;37:280-287.
2. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. HEPATOLOGY 2005;41:553-558.
3. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131-139.
4. Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirthosis. Gastroenterology 1991;101:1382-1390.
5. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. HEPATOLOGY 1996;23:1377-1383.
6. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174.
7. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001;85:584-595.
8. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004;91:267-275.
9. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-619.
10. Beer JH, Clerici N, Baillod P, von Felten A, Schlappritzi E, Buchi L. Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis. Thromb Haemost 1995;73:601-609.
11. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-2735.
12. Federici AB, Berkowitz SD, Lattuada A, Mannucci PM. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 1993;81:720-725.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
14. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded VWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999;82:1386-1389.
15. Brosstad F, Kjonniksen I, Ronning B, Stormorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986;55:276-278.
16. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88:2951-2958.
17. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003;101:1864-1870.
18. Sixma JJ, de Groot PG, van Zanten H, Ijsseldijk M. A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb Res 1998;92:S43-S46.
19. Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Arteriosclerosis 1990;10:49-61.
20. Moller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001;61:421-422.
21. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999;94:179-185.
22. Ben Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999;94:2977-2982.
23. van Mourik JA, Romani de Witt. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost 2001;86:164-171.
24. Takagi J, Kasahara K, Sekiya F, Inada Y, Saito Y. A collagen-binding glycoprotein from bovine platelets is identical to propolypeptide of von Willebrand factor. J Biol Chem 1989;264:10425-10430.
25. Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y. Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor. J Biol Chem 1989;264:6017-6020.
26. Studt JD, Bohm M, Budde U, Girma JP, Varadi K, Lammle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003;1:1882-1887.
27. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-41063.
28. Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004;313:212-216.
29. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005;106:922-924.
30. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.